Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;40(12):543-548.
doi: 10.1089/jir.2020.0214.

Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2

Hongjie Xia  1 , Pei-Yong Shi  1   2   3   4
Affiliations
Review

Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2

Hongjie Xia et al. J Interferon Cytokine Res. 2020 Dec.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting urgent study of the molecular mechanisms of SARS-CoV-2 infection and host immune response. Type I interferon (IFN-I) is a key component of host innate immune system responsible for eliminating the virus at the early stage of infection. In contrast, SARS-CoV-2 has evolved multiple strategies to evade innate immune response to facilitate viral replication, transmission, and pathogenesis. This review summarizes the recent progresses on SARS-CoV-2 proteins that antagonize host IFN-I production and/or signaling. These progresses have provided knowledge for new vaccine and antiviral development to prevent and control COVID-19.

Keywords: COVID-19; SARS-CoV-2; immune evasion; interferon.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
SARS-CoV-2 proteins antagonize host IFN-I response. (A) Genome structure of SARS-CoV-2. The opening reading frames are shown, including ORF1ab (nonstructural proteins), structural proteins, and accessory proteins. (B) Evasion of IFN-I by SARS-CoV-2 proteins. The inhibitory targets of IFN-I production (left) and signaling (right) are indicated. Viral proteins with IFN-I inhibitory activities but with unknown targets are indicated in red boxes and question marks. See text for details. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IFN-I, type I interferon.
See this image and copyright information in PMC

References

    1. Acharya D, Liu G, Gack MU. 2020. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 20(7):397–398 - PMC - PubMed
    1. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. 2013. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio 4(4):e00524-13 - PMC - PubMed
    1. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, et al. 2013. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13(9):752–761 - PMC - PubMed
    1. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, Barber GN. 2000. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13(1):129–141 - PubMed
    1. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, et al. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181(5):1036–1045.e9 - PMC - PubMed

Publication types